Do the lack of efficacy and the increase in the risk of skin cancer seen in Phase III trials of Eli Lilly's γ-secretase inhibitor undermine the potential of targeting this enzyme for the treatment of Alzheimer's disease?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Notch signaling pathway: architecture, disease, and therapeutics
Signal Transduction and Targeted Therapy Open Access 24 March 2022
-
A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease
Molecular Neurodegeneration Open Access 29 April 2016
-
Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia
BMC Neuroscience Open Access 19 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Extance, A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9, 749–751 (2010). https://doi.org/10.1038/nrd3288
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3288
This article is cited by
-
Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and Aβ Burden in Alzheimer's Disease
Neurotherapeutics (2023)
-
Notch signaling pathway: architecture, disease, and therapeutics
Signal Transduction and Targeted Therapy (2022)
-
Molecular progression of head and neck squamous cell carcinoma
The Nucleus (2017)
-
A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease
Molecular Neurodegeneration (2016)
-
Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia
BMC Neuroscience (2015)
